Verb Biotics Reveals GABA-Producing Probiotic LP815™ Effectively Eases Anxiety

In a significant breakthrough for gut-brain health, Verb Biotics has announced the successful completion of a clinical trial in collaboration with the decentralized clinical research organization, People Science. The trial, which focused on the probiotic strain Lactiplantibacillus plantarum LP815™, revealed promising results in reducing anxiety among adults experiencing mild to moderate symptoms.

The study was a six-week, randomized, double-blind, placebo-controlled trial aiming to evaluate the impact of LP815™ on anxiety, mood, sleep, and quality of life. The trial involved a diverse group of participants, with women constituting 63% of the total group. Participants who received a daily dose of 5 billion CFU of LP815™ showed a substantial reduction in anxiety levels. Remarkably, 68% of these participants improved by more than one category on the GAD-7 anxiety scale by the sixth week, compared to just 26% among those receiving a placebo.

Conducted through People Science's state-of-the-art digital platform, Chloe, the trial underscores a broader objective of increasing accessibility to clinical research. According to Belinda Tan, Co-CEO and Co-founder of People Science, this approach can significantly empower personal wellness journeys by providing reliable data to individuals.

Todd Beckman, CEO of Verb Biotics, emphasized the importance of this trial in advancing the understanding of GABA-producing probiotics and their effect on mental well-being through the gut-brain axis. He highlighted the collaboration with People Science as instrumental in delivering a robust clinical study that confirms the safety and efficacy of LP815™ as a mental wellness solution.

GABA, or gamma-aminobutyric acid, is a critical neurotransmitter in the brain, known for its role in mood regulation and sleep improvement. Verb Biotics is at the forefront of developing health solutions like LP815™, meeting the rising demand for natural, scientifically validated mental wellness products.

Chief Scientific Officer at Verb Biotics, Noah Zimmerman, PhD, noted the importance of GABA within the central nervous system and how targeted microbial interventions can lead to measurable improvements in mental health outcomes. He described the study as a vital demonstration of how gut-brain axis solutions can be designed to enhance quality of life effectively.

The study's findings contribute to a growing body of evidence supporting the use of gut microbiome interventions, particularly those focusing on the gut-brain axis, as innovative solutions for accessible mental wellness. In light of these promising results, Verb Biotics is gearing up for a new clinical study to explore the impact of LP815™ on sleep quality, furthering scientific insights into the strain's benefits for mental health.

Verb Biotics is committed to advancing microbiome innovation to enhance the health of humans and companion animals. Their "biotic" ingredients target specific functional health categories, such as gut-brain health, representing a new era in health solutions.

People Science, known for pioneering decentralized clinical trials, is dedicated to revolutionizing clinical research by making it more accessible and efficient. Their focus on data-driven solutions aims to transform traditional research methodologies, bringing new insights and innovations to the field.

This collaborative effort between Verb Biotics and People Science not only highlights the potential of LP815™ in managing anxiety but also sets the stage for future research into probiotic solutions for mental health and wellness.